This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
by Zacks Equity Research
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
by Zacks Equity Research
Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
by Zacks Equity Research
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
by Zacks Equity Research
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
by Zacks Equity Research
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
by Zacks Equity Research
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
by Zacks Equity Research
FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
by Zacks Equity Research
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Elanco (ELAN) Stock Declines After Sale of Aqua Business
by Zacks Equity Research
Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical (GMED) Global Sales, Innovation Aid Growth
by Zacks Equity Research
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
by Zacks Equity Research
Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
by Zacks Equity Research
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
by Zacks Equity Research
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note
by Zacks Equity Research
QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.
McKesson (MCK) Gains 26% Year to Date: What's Backing the Rally?
by Zacks Equity Research
McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.